|Ms. Heather Bresch||CEO & Exec. Director||4.27M||N/A||48|
|Mr. Rajiv Malik||Pres & Exec. Director||2.85M||N/A||56|
|Mr. Kenneth S. Parks||Chief Financial Officer||1.44M||N/A||54|
|Mr. Anthony Mauro||Chief Commercial Officer||1.87M||N/A||44|
|Mr. Paul B. Campbell||Chief Accounting Officer, Sr. VP and Corp. Controller||N/A||N/A||N/A|
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.
Mylan N.V.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 10.